Ascletis In-Licenses China Rights to an HCV Treatment from Medivir

Ascletis of Hangzhou has in-licensed a third HCV treatment. Its latest acquisition is a nucleotide polymerase inhibitor from Medivir AB of Sweden. Ascletis acquired greater China rights for the antiviral, a NS5B inhibitor that has not yet started clinical trials. Ascletis' two other HCV treatments are in late-stage development, and the company hopes to market an all-oral, non-ribavirin combination HCV treatment in China soon. Ascletis made an upfront payment to Medivir and will pay milestones and royalties, though details of the agreement were not disclosed. More details.... Stock Symbol: (NSDQ: MVIR) Share this with colleagues: // //